AstraZeneca Says BRILINTA Not Yet Approved; Expecting Approval Decision Soon

After calling the company to confirm the earlier rumor posted

, a spokesperson for AstraZeneca

says that BRILINTA has not yet received FDA approval. Nevertheless, the company "expects" approval soon, according to the call. AstraZeneca is currently trading at $50/share in post-market trading after rumors of FDA approval circulated. This represents a premium of 1% to its closing price.